Bronchogen
Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu, AEDL)
Overview
Bronchogen is a Khavinson-class short-peptide bioregulator with the sequence Ala-Glu-Asp-Leu (AEDL), targeting respiratory-tissue regulatory pathways within the broader Khavinson bioregulator framework. The molecule was developed at the St. Petersburg Institute of Bioregulation and Gerontology as the respiratory-tissue member of the Khavinson short-peptide family, alongside Cortagen (cerebral cortex, AEDP), Pinealon (cognitive, EDR), Vesugen (vascular, KED), Cardiogen (cardiovascular), and others. The shared hypothesis is that short tissue-specific peptide fragments isolated from animal tissues act as endogenous bioregulators of cell-cycle and gene-expression programs in their target tissues; Bronchogen specifically is positioned in the Russian-school research literature as a regulatory peptide for bronchial epithelium and respiratory-tissue maintenance. Lyochem supplies Bronchogen as a lyophilized 20 mg vial at ≥99.0% HPLC purity. CAS is not consistently registered across suppliers for the Khavinson bioregulator class, so identity is established via sequence verification by LC-MS/MS plus mass-spec confirmation of the AEDL tetrapeptide on every batch COA, particularly important because the four members of the Khavinson tetrapeptide family (AEDG / AEDL / AEDP / KED) are close in mass and require explicit sequencing to disambiguate.
Who buys this, and why
Khavinson short bioregulators — Admax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen — ship to research labs replicating Russian-school protocols or running comparative tissue-specific peptide-bioregulator studies. The published literature base for this class is concentrated in Russian-language sources; buyers should expect to consult that literature directly for protocol selection. Analytical-packet expectations are the same as any other lyophilised research peptide.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- (verification pending, please confirm via COA)
- Sequence
- AEDL
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 20 mg
- MOQ
- On request
- Lead time
- 14–21 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Source-literature pointer (Russian-language references on request)
- Stability at −20 °C across 12 months
- Sequence ladder available on request
Regulatory note
Khavinson bioregulator (Russian scientific lineage); CAS commonly not registered. Confirm AEDL sequence and identity per batch COA, disambiguation from sibling tetrapeptides (AEDG / AEDP / KED) in the family is essential since the masses are close.
Frequently asked questions
How do I tell Bronchogen apart from its sibling Khavinson tetrapeptides (Epitalon, Cortagen)?▾
The Khavinson tetrapeptide family shares an Ala-Glu-Asp tripeptide core (AED-) and differs only in the fourth C-terminal residue: Bronchogen is AEDL (with Leucine), Epitalon is AEDG (Glycine), Cortagen is AEDP (Proline). The molecular weights are close (Bronchogen ≈432 Da, Epitalon ≈390 Da, Cortagen ≈400 Da, all within a 50 Da range), which means mass spec alone is insufficient to disambiguate, the molecules can be confused on the COA if only mass is reported. LC-MS/MS sequence verification covering the full b- and y-ion ladder is the definitive identity check. Buyers ordering any single Khavinson tetrapeptide should request explicit sequence-verification data on the batch COA, especially when sourcing from a new supplier.
What's the published Khavinson-school research context for Bronchogen specifically?▾
Khavinson-school publications on Bronchogen focus on respiratory-epithelium gene-expression effects in animal models of chronic bronchopulmonary disease and aging-related respiratory decline. The reported readouts include modulation of bronchial epithelial cell proliferation markers, antioxidant-enzyme expression in respiratory tissue, and improvements in pulmonary function metrics in aged-rat models. As with the rest of the Khavinson framework, the evidence base is concentrated in Russian-language journals and translated proceedings from the St. Petersburg Institute of Bioregulation and Gerontology, Western peer-reviewed coverage is limited and the mechanism-of-action data has not been independently replicated outside the Khavinson research lineage at the rigor level Western evidence-based-medicine frameworks expect. Buyers working with Bronchogen should reference the Khavinson primary literature for protocol design and treat the molecule as an investigational research tool.
What's the typical administration route used in Bronchogen research protocols?▾
Published Khavinson-school Bronchogen protocols use both intranasal and intramuscular administration routes. The intranasal route is the more commonly used in respiratory-focused research because direct delivery to the airway epithelium maximizes tissue exposure at the target organ. The intramuscular route produces systemic exposure that is appropriate for studies examining whole-organism effects rather than direct airway-tissue interaction. Working dilutions for intranasal preparation should use isotonic saline as the vehicle with neutral pH (5.5-7.0); benzalkonium chloride and similar quaternary-ammonium preservatives should be avoided in intranasal peptide formulations because they interact with short peptide sequences.
Related peptides
Buyers who view Bronchogen also ask about:
Cardiogen
≥99.0%Khavinson cardiovascular short-peptide bioregulator
- CAS
- —
- Vial
- 20 mg
4-mer
Cortagen
≥99.0%Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
- CAS
- —
- Vial
- 20 mg
3-mer
Pinealon
≥99.0%Khavinson neuroprotective tripeptide (Glu-Asp-Arg, EDR)
- CAS
- 175175-23-2
- Vial
- 5 mg–20 mg